Clin2
NCT07302854Possibly a fitRecruiting

Clot-busting medicine for medium vessel strokes

Acute Ischemic StrokeMedium Vessel Occlusion

Treatments studied

Part of Brain & nervous system, Heart & circulation clinical trials.

This trial tests a new clot-busting medicine called tenecteplase, given directly into the blood vessel in the brain, to treat strokes caused by a blockage in a medium-sized artery. The goal is to see if it can help restore blood flow and reduce disability, especially for patients who can be treated within 24 hours of stroke onset.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2/Phase 3
Enrollment
382 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You are 18 years or older.
  • You were able to take care of yourself before the stroke (no major disability).
  • Your stroke causes noticeable problems like trouble speaking, weakness, or vision loss.
  • A CT or MRI scan shows a blockage in a medium-sized blood vessel in your brain.
  • Your stroke started within the last 24 hours, and there is a special brain scan showing that some brain tissue is still salvageable.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06559436Recruiting
Extending window for clot-busting drug in medium vessel stroke

This trial tests a clot-dissolving drug called tenecteplase given 4.5 to 24 hours after a stroke caused by a blockage in a medium-sized brain artery. It aims to see if waiting longer than usual still helps reduce disability.

Hefei, Anhui
NCT07469293Not yet recruiting· Phase 3
Study of artery-injected tenecteplase for stroke with medium vessel blockage

This trial tests a clot-busting drug called tenecteplase, given directly into the blocked artery, for people who have had a stroke caused by a medium-sized brain vessel blockage within the last 24 hours. It aims to see if this treatment is safe and effective in improving recovery.

Baise City, Guangxi
NCT07137832Recruiting· Phase 3
Testing clot-busting drug during stroke treatment for medium vessel blockages

This trial tests whether giving a clot-dissolving medication directly into the brain's blood vessels during a standard procedure (mechanical thrombectomy) can improve outcomes for people with a stroke caused by a blockage in a medium-sized artery. It may be an option for patients who arrive at the hospital within 24 hours of symptom onset and have enough salvageable brain tissue.

Guangzhou, Guangdong
NCT07357987Recruiting· Phase 3
Stroke treatment with tenecteplase via artery

This trial tests a clot-busting drug called tenecteplase given directly into the brain artery for people having a moderate stroke caused by a blockage in a medium-sized blood vessel. The goal is to see if it helps improve recovery when given within 24 hours of stroke symptoms starting.

Beijing, Beijing Municipality
NCT07185022Recruiting
Clot-busting drug through artery for medium-vessel stroke

This trial tests a clot-busting drug given directly into the arteries of the brain for people who have had a stroke due to a blockage in a medium-sized artery. It aims to see if this treatment can help improve recovery when started up to 72 hours after symptoms begin.

Fuyang, Anhui
NCT06781385Enrolling by invitation· Phase 2
Tenecteplase after clot removal for severe stroke

This trial tests if giving a clot-busting drug (tenecteplase) directly into the brain artery after a successful clot-removal procedure can improve outcomes for people with a major stroke. It is for patients who had a large vessel blockage and received endovascular thrombectomy within 24 hours of symptoms starting.

Charlotte, North Carolina

Hear when a new Acute Ischemic Stroke trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.